Dellas, Claudia

[["dc.bibliographiccitation.issue","48"],["dc.bibliographiccitation.journal","DMW - Deutsche Medizinische Wochenschrift"],["dc.bibliographiccitation.volume","133"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Konstantinides, Stavros V."],["dc.date.accessioned","2018-11-07T11:08:55Z"],["dc.date.available","2018-11-07T11:08:55Z"],["dc.date.issued","2008"],["dc.format.extent","2511"],["dc.identifier.doi","10.1055/s-0028-1100948"],["dc.identifier.isi","000261573800005"],["dc.identifier.pmid","19021083"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52899"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0012-0472"],["dc.title","Operative treatment in pelvic vein thrombose contra"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","124"],["dc.bibliographiccitation.issue","17"],["dc.bibliographiccitation.journal","Circulation"],["dc.bibliographiccitation.lastpage","125"],["dc.bibliographiccitation.volume","110"],["dc.contributor.author","Schafer, K."],["dc.contributor.author","Schremmer, C."],["dc.contributor.author","Dellas, Claudia"],["dc.date.accessioned","2018-11-07T10:44:37Z"],["dc.date.available","2018-11-07T10:44:37Z"],["dc.date.issued","2004"],["dc.identifier.isi","000224783500590"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47312"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.conference","77th Scientific Meeting of the American-Heart-Association"],["dc.relation.eventlocation","New Orleans, LA"],["dc.relation.issn","0009-7322"],["dc.title","Lack of urokinase plasminogen activator promotes instability of vascular lesions in apolipoprotein E-knockout mice"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0246169"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Geyer, Siegfried"],["dc.contributor.author","Fleig, Katharina"],["dc.contributor.author","Norozi, Kambiz"],["dc.contributor.author","Röbbel, Lena"],["dc.contributor.author","Paul, Thomas"],["dc.contributor.author","Müller, Matthias"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.editor","Leist, Anja K."],["dc.date.accessioned","2021-04-14T08:28:04Z"],["dc.date.available","2021-04-14T08:28:04Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1371/journal.pone.0246169"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82494"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1932-6203"],["dc.title","Life chances after surgery of congenital heart disease: A case-control-study of inter- and intragenerational social mobility over 15 years"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","144"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Internal Medicine"],["dc.bibliographiccitation.lastpage","154"],["dc.bibliographiccitation.volume","275"],["dc.contributor.author","Czepluch, Frauke S."],["dc.contributor.author","Kuschicke, Hendrik"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Schaefer, Katrin"],["dc.date.accessioned","2017-09-07T11:46:53Z"],["dc.date.available","2017-09-07T11:46:53Z"],["dc.date.issued","2014"],["dc.description.abstract","BackgroundMonocytes and platelets are important cellular mediators of atherosclerosis. Human monocytes can be divided into CD14(++)CD16(-), CD14(++)CD16(+) and CD14(+)CD16(++) cells, which differ in their functional properties. The aim of this study was to examine monocyte subset distribution, monocyte-platelet aggregate (MPA) formation and expression of CCR5, the receptor of the platelet-derived chemokine CCL5, and to determine whether these parameters are altered in individuals with coronary atherosclerosis. MethodsPeripheral blood cells from 64 healthy blood donors (HBDs) and 60 patients with stable coronary artery disease (CAD) were stained with antibodies against CD14, CD16, CD42b and CCR5 and analysed by flow cytometry. Circulating CCL5 levels were determined using an enzyme-linked immunosorbent assay. ResultsIn patients with CAD, the relative proportion of the CD14(++)CD16(-) monocyte subset was elevated (P<0.05) and of the CD14(+)CD16(++) subset was reduced (P<0.001) compared with the HBD group. Furthermore, MPA formation significantly increased in patients with CAD in all three monocyte subsets. In both study groups, the majority of CCR5(+) cells was detected in CD14(++)CD16(+) monocytes (P<0.001 versus CD14(++)CD16(-) and CD14(+)CD16(++)), although the CCR5(+) monocyte number was reduced in patients with CAD (CD14(++)CD16(-)/CD14(+)CD16(++), P<0.001; CD14(++)CD16(+), P<0.05) compared with the HBD group, particularly in those who were not taking statins. Ex vivo incubation of monocytes from HBDs with plasma from patients with CAD also decreased CCR5(+) expression (P<0.05 versus plasma from HBDs). Serum CCL5 levels were similar in both groups. ConclusionsThe increased monocyte-platelet cross-talk in patients with CAD might have contributed to atherosclerosis progression. The decreased CCR5(+) monocyte numbers in patients with CAD could have resulted from CCR5(+) cell recruitment into atherosclerotic lesions or CCR5 downregulation in response to circulating factors."],["dc.identifier.doi","10.1111/joim.12145"],["dc.identifier.gro","3142194"],["dc.identifier.isi","000329764500006"],["dc.identifier.pmid","24118494"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/5577"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: University Medical Center Gottingen"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.eissn","1365-2796"],["dc.relation.issn","0954-6820"],["dc.title","Increased proatherogenic monocyte-platelet cross-talk in monocyte subpopulations of patients with stable coronary artery disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","996"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Thrombosis and Haemostasis"],["dc.bibliographiccitation.lastpage","1003"],["dc.bibliographiccitation.volume","111"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Tschepe, Merle"],["dc.contributor.author","Seeber, Valerie"],["dc.contributor.author","Zwiener, Isabella"],["dc.contributor.author","Kuhnert, Katherina"],["dc.contributor.author","Schaefer, Katrin"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Konstantinides, Stavros"],["dc.contributor.author","Lankeit, Mareike"],["dc.date.accessioned","2017-09-07T11:46:17Z"],["dc.date.available","2017-09-07T11:46:17Z"],["dc.date.issued","2014"],["dc.description.abstract","We tested whether heart-type fatty acid binding protein (H-FABP) measured by a fully-automated immunoturbidimetric assay in comparison to ELISA provides additive prognostic value in patients with pulmonary embolism (PE), and validated a fast prognostic score in comparison to the ESC risk prediction model and the simplified Pulmonary Embolism Severity Index (sPESI). We prospectively examined 271 normotensive patients with PE; of those, 20 (7%) had an adverse 30-day outcome. H-FABP levels determined by immunoturbidimetry were higher (median, 5.2 [IQR; 2.7-9.8] ng/ml) than those by ELISA (2.9 [1.1-5.4] ng/ml), but Bland-Altman plot demonstrated a good agreement of both assays. The area under the curve for H-FABP was greater for immunoturbidimetry than for ELISA (0.82 [0.74-0.91] vs 0.78 [0.68-0.89]; P=0.039). H-FABP measured by immunoturbidimetry (but not by ELISA) provided additive prognostic information to other predictors of 30-day outcome (OR, 12.4 [95% CI, 1.6-97.6]; P=0.017).When H-FABP determined by immunoturbidimetry was integrated into a novel prognostic score (H-FABP, Syncope, and Tachycardia; FAST score), the score provided additive prognostic information by multivariable analysis (OR, 14.2 [3.9-51.4]; p<0.001; c-index, 0.86) which were superior to information obtained by the ESC model(c-index, 0.62; net reclassification improvement (NRI), 0.39 [0.21-0.56]; P<0.001) or the sPESI (c-index, 0.68; NRI, 0.24 [0.05-0.43]; P=0.012). In conclusion, determination of H-FABP by immunoturbidimetry provides prognostic information superior to that of ELISA and, if integrated in the FAST score, appears more suitable to identify patients with an adverse 30-day outcome compared to the ESC model and sPESI."],["dc.identifier.doi","10.1160/TH13-08-0663"],["dc.identifier.gro","3142135"],["dc.identifier.isi","000335541500025"],["dc.identifier.pmid","24477222"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/4933"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Schattauer Gmbh-verlag Medizin Naturwissenschaften"],["dc.relation.issn","0340-6245"],["dc.title","A novel H-FABP assay and a fast prognostic score for risk assessment of normotensive pulmonary embolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","796"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Thrombosis Research"],["dc.bibliographiccitation.lastpage","801"],["dc.bibliographiccitation.volume","135"],["dc.contributor.author","Klok, F. A."],["dc.contributor.author","Tesche, C."],["dc.contributor.author","Rappold, L."],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Huisman, M. V."],["dc.contributor.author","Konstantinides, Stavros"],["dc.contributor.author","Lankeit, Mareike"],["dc.date.accessioned","2017-09-07T11:44:25Z"],["dc.date.available","2017-09-07T11:44:25Z"],["dc.date.issued","2015"],["dc.description.abstract","Purpose: International guidelines do not provide strong recommendations on the duration and intensity of follow-up after acute pulmonary embolism(PE), nor on screening-programs for chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to address this gab by performing an external validation of the easy \"CTEPH rule-out-criteria\" based on a normal NT-proBNP level and the absence of 3 ECG characteristics. Methods: 134 patients underwent clinical follow-up 6 months after PE. Predefined transthoracic echocardiographic (TTE) criteria were used to categorize patients as \"PH unlikely\" or \"PH possible/likely\". The latter patients underwent further (invasive) diagnostic procedures to confirm and classify the diagnosis of pulmonary hypertension. NT-proBNP and ECGs, both assessed at the day of echocardiography, were evaluated post-hoc. Results: Sixty-three patients (47%) scored none of the \"CTEPH rule-out criteria\" positive, of whom 61 had normal TTE (97%). Twenty-five patients (19%) were categorized by TTE as \"PH possible/likely\"; of those, 6 were diagnosed with CTEPH. The sensitivity of rule-out criteria for CTEPH was 100% (95%CI 56-100%; 6/6 patients identified), and for \"PH possible/likely\" on TTE 92% (95%CI 74-99%; 23/25 patients identified): 2 asymptomatic patients with estimated systolic pulmonary arterial pressure of 36 mmHg and 38 mmHg, respectively, who remained stable during further 2-year follow-up, were not identified. Inter-observer agreement for the adjudication of the ECG characteristics was excellent (kappa-statistic 0.97). Conclusions: In this external validation cohort, we confirmed the diagnostic accuracy and reproducibility of the \"CTEPH rule-out criteria\". These results provide a solid ground for future outcome trials applying this algorithm. (C) 2014 Published by Elsevier Ltd."],["dc.identifier.doi","10.1016/j.thromres.2014.12.009"],["dc.identifier.gro","3141915"],["dc.identifier.isi","000353490800005"],["dc.identifier.pmid","25746363"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/2489"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0049-3848"],["dc.title","External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","220"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Thrombosis and Haemostasis"],["dc.bibliographiccitation.lastpage","227"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Schremmer, Carmen"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Konstantinides, Stavros V."],["dc.contributor.author","Schaefer, Katrin"],["dc.date.accessioned","2017-09-07T11:49:27Z"],["dc.date.available","2017-09-07T11:49:27Z"],["dc.date.issued","2007"],["dc.description.abstract","Urokinase plasminogen activator (uPA) is strongly expressed in atherosclerotic lesions, but the overall effect of the protease on plaque composition and growth remains controversial. In the present study, apolipoprotein E-deficient (apoE(-/-)) mice were intercrossed with mice which were lacking the uPA gene (double-knockout; DKO). In ferric chloride-induced carotid artery lesions in chow-fed mice, uPA deficiency increased neointimal size (P=0.015) and luminal stenosis (P=0.014), while reducing media thickness (P=0.002). A lack of uPA also increased the size of and the luminal obstruction from atherosclerotic plaques at the coronary and brachiocephalic arteries of apoE(-/-) mice. Plaques were characterised by a higher fibrinogen/fibrin content and a decrease in cellularity and collagen content. When apoE(-/-) and DKO mice were analysed as a single group, a significant-correlation was found between the (x-actin (smooth muscle cell) and collagen content of atherosclerotic lesions (r = 0.554; P < 0.05), and a negative correlation existed between the a-actin and fibrin/fibrinogen immunopositive area (r = -0.79 1; P < 0.001). Further analysis of brachiocephalic atherosclerosis, a predilection site for plaque rupture in the apoE(-/-) mouse, revealed signs of plaque vulnerability, including a reduced cap-to-intima ratio (0.21 +/- 0.04 vs. 0.37 +/- 0.05; P=0.03) and more frequent detection of intraplaque haemorrhage (56% vs. 13%; P < 0.01) and buried fibrous caps (1.8 +/- 0.5 vs. 0.5 +/- 0.2; P=0.02) in DKO compared to apoE(-/-) mice. These results indicate that, at least at (patho) physiologic concentrations, uPA is essential for maintaining the cellularity and collagen content and, possibly, the stability of lesions, both by preventing excessive intramural fibrin accumulation and by facilitating cell migration and invasion."],["dc.identifier.doi","10.1160/TH06-09-0508"],["dc.identifier.gro","3143478"],["dc.identifier.isi","000248180700037"],["dc.identifier.pmid","17598016"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/996"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","0340-6245"],["dc.title","Lack of urokinase plasminogen activator promotes progression and instability of atherosclerotic lesions in apolipoprotein E-knockout mice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1402"],["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","New England Journal of Medicine"],["dc.bibliographiccitation.lastpage","1411"],["dc.bibliographiccitation.volume","370"],["dc.contributor.author","Meyer, Guy"],["dc.contributor.author","Vicaut, Eric"],["dc.contributor.author","Danays, Thierry"],["dc.contributor.author","Agnelli, Giancarlo"],["dc.contributor.author","Becattini, Cecilia"],["dc.contributor.author","Beyer-Westendorf, Jan"],["dc.contributor.author","Bluhmki, Erich"],["dc.contributor.author","Bouvaist, Helene"],["dc.contributor.author","Brenner, Benjamin"],["dc.contributor.author","Couturaud, Francis"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Empen, Klaus"],["dc.contributor.author","Franca, Ana"],["dc.contributor.author","Galie, Nazzareno"],["dc.contributor.author","Geibel, Annette"],["dc.contributor.author","Goldhaber, Samuel Z."],["dc.contributor.author","Jimenez, David"],["dc.contributor.author","Kozak, Matija"],["dc.contributor.author","Kupatt, Christian"],["dc.contributor.author","Kucher, Nils"],["dc.contributor.author","Lang, Irene M."],["dc.contributor.author","Lankeit, Mareike K."],["dc.contributor.author","Meneveau, Nicolas"],["dc.contributor.author","Pacouret, Gerard"],["dc.contributor.author","Palazzini, Massimiliano"],["dc.contributor.author","Petris, Antoniu"],["dc.contributor.author","Pruszczyk, Piotr"],["dc.contributor.author","Rugolotto, Matteo"],["dc.contributor.author","Salvi, Aldo"],["dc.contributor.author","Schellong, Sebastian"],["dc.contributor.author","Sebbane, Mustapha"],["dc.contributor.author","Sobkowicz, Bozena"],["dc.contributor.author","Stefanovic, Branislav S."],["dc.contributor.author","Thiele, Holger"],["dc.contributor.author","Torbicki, Adam"],["dc.contributor.author","Verschuren, Franck"],["dc.contributor.author","Konstantinides, Stavros V."],["dc.date.accessioned","2018-11-07T09:41:18Z"],["dc.date.available","2018-11-07T09:41:18Z"],["dc.date.issued","2014"],["dc.description.abstract","BackgroundThe role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. MethodsIn a randomized, double-blind trial, we compared tenecteplase plus heparin with placebo plus heparin in normotensive patients with intermediate-risk pulmonary embolism. Eligible patients had right ventricular dysfunction on echocardiography or computed tomography, as well as myocardial injury as indicated by a positive test for cardiac troponin I or troponin T. The primary outcome was death or hemodynamic decompensation (or collapse) within 7 days after randomization. The main safety outcomes were major extracranial bleeding and ischemic or hemorrhagic stroke within 7 days after randomization. ResultsOf 1006 patients who underwent randomization, 1005 were included in the intention-to-treat analysis. Death or hemodynamic decompensation occurred in 13 of 506 patients (2.6%) in the tenecteplase group as compared with 28 of 499 (5.6%) in the placebo group (odds ratio, 0.44; 95% confidence interval, 0.23 to 0.87; P=0.02). Between randomization and day 7, a total of 6 patients (1.2%) in the tenecteplase group and 9 (1.8%) in the placebo group died (P=0.42). Extracranial bleeding occurred in 32 patients (6.3%) in the tenecteplase group and 6 patients (1.2%) in the placebo group (P<0.001). Stroke occurred in 12 patients (2.4%) in the tenecteplase group and was hemorrhagic in 10 patients; 1 patient (0.2%) in the placebo group had a stroke, which was hemorrhagic (P=0.003). By day 30, a total of 12 patients (2.4%) in the tenecteplase group and 16 patients (3.2%) in the placebo group had died (P=0.42). ConclusionsIn patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke. (Funded by the Programme Hospitalier de Recherche Clinique in France and others; PEITHO EudraCT number, 2006-005328-18; ClinicalTrials.gov number, NCT00639743.) In a randomized trial, 1006 patients with intermediate-risk pulmonary embolism were assigned to tenecteplase or placebo in addition to standard heparin therapy. The tenecteplase group had a lower rate of hemodynamic decompensation but more frequent major hemorrhage and stroke. Acute pulmonary embolism occurs frequently and may cause death or serious disability.(1) Case fatality rates vary widely,(2),(3) but approximately 10% of all patients with acute pulmonary embolism die within 3 months after the diagnosis.(4),(5) Acute right ventricular pressure overload at diagnosis is an important determinant of the severity and early clinical outcome of pulmonary embolism.(6) High-risk pulmonary embolism(7) is characterized by overt hemodynamic instability and warrants immediate advanced therapy, including consideration of fibrinolysis. In contrast, for patients presenting without systemic hypotension or hemodynamic compromise, standard anticoagulation is generally considered adequate treatment.(8) However, patients who have acute right ventricular ..."],["dc.identifier.doi","10.1056/NEJMoa1302097"],["dc.identifier.isi","000334095200008"],["dc.identifier.pmid","24716681"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33698"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Massachusetts Medical Soc"],["dc.relation.issn","1533-4406"],["dc.relation.issn","0028-4793"],["dc.title","Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","204"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","International Journal of Obesity"],["dc.bibliographiccitation.lastpage","210"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Lankeit, Mareike"],["dc.contributor.author","Reiner, Christian"],["dc.contributor.author","Schaefer, Katrin"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Konstantinides, Stavros"],["dc.date.accessioned","2017-09-07T11:48:18Z"],["dc.date.available","2017-09-07T11:48:18Z"],["dc.date.issued","2013"],["dc.description.abstract","OBJECTIVE: The adipocytokine leptin is an independent cardiovascular risk factor and exerts prothrombotic effects, both in arterial and venous thrombosis. We therefore investigated the relationship between leptin levels and clinical outcome in patients with acute pulmonary embolism (PE). DESIGN: We prospectively studied consecutive patients with confirmed acute PE admitted at the University Hospital of Goettingen (Germany) between 2003 and 2009. SUBJECTS: The study subjects were a total of 264 patients with PE (median age, 68 years; interquartile range, 53-75; 60% women; body mass index (BMI) 27 kgm(-2) (24.1-31.2)). Leptin levels were determined by a commercially available enzyme-linked immunosorbent assay. Patients were followed for an adverse 30-day outcome, that is, death, circulatory collapse with need for catecholamines, intubation or resuscitation, and for long-term survival. RESULTS: The median leptin level was 10.1 ng ml(-1) (3.7-25.2). Patients (n = 49; 18.6%) with a complicated 30-day course had significantly lower leptin levels (5.3 ng ml(-1) (1.8-19.7) compared with patients without complications (10.4 ng ml(-1) (4.7-25.5), P = 0.02). When leptin was analyzed as a continuous variable, there was a significant 36% increase in the relative risk for early complications for every decrease in the natural logarithm of leptin by one s.d. (odds ratio (OR) 1.36 (1.06-1.76), P = 0.017), independently of BMI (BMI-adjusted OR, 1.52 (1.13-2.05), P = 0.006). In addition, patients within the lowest leptin tertile had a 2.8- and 2.3-fold increased risk for 30-day-complications, compared with those in the middle (P = 0.011) and high tertile (P = 0.030), and a worse probability of long-term survival (log-rank; P = 0.018). CONCLUSION: Low plasma leptin concentration is a predictor for a complicated course and high mortality in patients with acute PE. This association is independent of known factors affecting leptin levels, including gender and obesity. International Journal of Obesity (2013) 37, 204-210; doi:10.1038/ijo.2012.36; published online 20 March 2012"],["dc.identifier.doi","10.1038/ijo.2012.36"],["dc.identifier.gro","3142393"],["dc.identifier.isi","000316932100008"],["dc.identifier.pmid","22430305"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7786"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: University of Goettingen (Heidenreich von Siebold-Programm)"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","0307-0565"],["dc.title","BMI-independent inverse relationship of plasma leptin levels with outcome in patients with acute pulmonary embolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","543"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Thrombosis Research"],["dc.bibliographiccitation.lastpage","547"],["dc.bibliographiccitation.volume","132"],["dc.contributor.author","Lankeit, Mareike"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Benz, Viola"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Konstantinides, Stavros"],["dc.date.accessioned","2017-09-07T11:47:05Z"],["dc.date.available","2017-09-07T11:47:05Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: Heart-type fatty acid-binding protein (H-FABP) is a useful biomarker for risk stratification of patients with pulmonary embolism(PE). In patients with acutemyocardial infarction, H-FABP plasma concentrations rise after 30 minutes and return to normal within 20-24 hours. We tested whether the predictive value of H-FABP is affected by the duration of symptoms prior to diagnosis in patients with PE. Material and Methods: We prospectively studied 257 consecutive normotensive patients with confirmed symptomatic PE. Results: Patients with acute (<24 hours; n = 150) symptom onset presented more often with syncope (28.7% vs. 6.5%; p < 0.001) compared to patients with symptoms >= 24 hours (n = 107); other baseline characteristics, comorbidities, and risk factors were distributed equally. Patients with an adverse 30-day outcome (6.6%) had higher H-FABP levels (11.84 [3.57-19.62] ng/ml) compared to patients with a favorable course (3.42 [1.92-5.42] ng/ml; p < 0.001). However, the proportion of patients with H-FABP levels >= 6 ng/ml did not differ among patients with acute symptom onset and late presentation (p = 0.104). Only tachycardia and elevation of H-FABP were associated with an increased risk of an adverse 30-day outcome both in patients with acute symptom onset (H-FABP: OR, 5.8; 95% CI, 1.4-24.5; p = 0.016; tachycardia: 7.0 [1.4-36.0]; p = 0.018) and late presentation (H-FABP: 9.3 [2.0-43.2]; p = 0.004 and tachycardia: 12.3 [1.5-103.6]; p = 0.021). The prognostic value could further be improved by the use of a simple H-FABP-based clinical prediction score. Conclusions: Our findings indicate that H-FABP is a useful biomarker for risk stratification of normotensive patients with PE regardless of symptom duration prior to diagnosis. (c) 2013 Published by Elsevier Ltd."],["dc.identifier.doi","10.1016/j.thromres.2013.09.022"],["dc.identifier.gro","3142264"],["dc.identifier.isi","000325752700010"],["dc.identifier.pmid","24094603"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/6354"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: German Federal Ministry of Education and Research [BMBF 01EO1003]"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0049-3848"],["dc.title","The predictive value of heart-type fatty acid-binding protein is independent from symptom duration in normotensive patients with pulmonary embolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]